A Randomized Trial of Progesterone in Women with Recurrent Miscarriages
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Progesterone is essential for the maintenance of pregnancy. However, whether progesterone supplementation in the first trimester of pregnancy would increase the rate of live births among women with a history of unexplained recurrent miscarriages is uncertain. METHODS: We conducted a multicenter, double-blind, placebo-controlled, randomized trial to investigate whether treatment with progesterone would increase the rates of live births and newborn survival among women with unexplained recurrent miscarriage. We randomly assigned women with recurrent miscarriages to receive twice-daily vaginal suppositories containing either 400 mg of micronized progesterone or matched placebo from a time soon after a positive urinary pregnancy test (and no later than 6 weeks of gestation) through 12 weeks of gestation. The primary outcome was live birth after 24 weeks of gestation. RESULTS: A total of 1568 women were assessed for eligibility, and 836 of these women who conceived naturally within 1 year and remained willing to participate in the trial were randomly assigned to receive either progesterone (404 women) or placebo (432 women). The follow-up rate for the primary outcome was 98.8% (826 of 836 women). In an intention-to-treat analysis, the rate of live births was 65.8% (262 of 398 women) in the progesterone group and 63.3% (271 of 428 women) in the placebo group (relative rate, 1.04; 95% confidence interval [CI], 0.94 to 1.15; rate difference, 2.5 percentage points; 95% CI, -4.0 to 9.0). There were no significant between-group differences in the rate of adverse events. CONCLUSIONS: Progesterone therapy in the first trimester of pregnancy did not result in a significantly higher rate of live births among women with a history of unexplained recurrent miscarriages. (Funded by the United Kingdom National Institute of Health Research; PROMISE Current Controlled Trials number, ISRCTN92644181.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Caution should be exercised when interpreting the results of these meta-analyses due to differences in the RCTs included in the analyses.199,200”
From Recurrent MiscarriageGreen‐top Guideline No. 17 (2023) · cites this paper as [199]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Kumar, A., Begum, N., Prasad, S., Aggarwal, S., & Sharma, S. (2014) · Fertility and Sterility · doi:10.1016/j.fertnstert.2014.07.1251 · Cited by 93
RetractedPeto, R., Pike, M. C., Armitage, P., Breslow, N. E., Cox, D. R., Howard, S. V., Mantel, N., McPherson, K., Peto, J., & Smith, P. G. (1976) · British Journal of Cancer · doi:10.1038/bjc.1976.220 · Cited by 2,294
Evaluation and treatment of recurrent pregnancy loss: a committee opinion
(2012) · Fertility and Sterility · doi:10.1016/j.fertnstert.2012.06.048 · Cited by 1,308
Rai, R., & Regan, L. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69204-0 · Cited by 1,227
Self-citationProgesterone and the Risk of Preterm Birth among Women with a Short Cervix
Fonseca, E. B., Celik, E., Parra, M., Singh, M., & Nicolaides, K. H. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067815 · Cited by 1,086
da Fonseca, E. B., Bittar, R. E., Carvalho, M. H. B., & Zugaib, M. (2003) · American Journal of Obstetrics and Gynecology · doi:10.1067/mob.2003.41 · Cited by 789
Cytogenetic analysis of miscarriages from couples with recurrent miscarriage: a case-control study
Stephenson, M. D. (2002) · Human Reproduction · doi:10.1093/humrep/17.2.446 · Cited by 522
A comparison of placental development and endocrine functions between the human and mouse model
Malassine, A., Frendo, J. L., & Evain-Brion, D. (2003) · Human Reproduction Update · doi:10.1093/humupd/dmg043 · Cited by 476
Targeted drug delivery in gynaecology: the first uterine pass effect
Bulletti, C., de Ziegler, D., Flamigni, C., Giacomucci, E., Polli, V., Bolelli, G., & Franceschetti, F. (1997) · Human Reproduction · doi:10.1093/humrep/12.5.1073 · Cited by 245
Progestogen for preventing miscarriage
Oates-Whitehead, R., Haas, D., & Carrier, J. (2003) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003511 · Cited by 224
Research works printed but not linked: 2
- Haas DM, 2013, Cochrane Database Syst Rev, 10, CD003511
- Levine L, 1964, West J Surg Obs Gynecol, 72, 30
Cited by
Items 101–200 of 309
Schumacher, A., Dauven, D., & Zenclussen, A. C. (2017) · American Journal of Reproductive Immunology · doi:10.1111/aji.12626 · Cited by 14
Ogwulu, C. B., Goranitis, I., Devall, A., Cheed, V., Gallos, I. D., Middleton, L. J., Harb, H., Williams, H., Eapen, A. K., DANIELS, J. P., et al. (2020) · BJOG An International Journal of Obstetrics & Gynaecology · doi:10.1111/1471-0528.16068 · Cited by 13
Self-citationBashiri, A., Galperin, G., Zeadna, A., Baumfeld, Y., & Wainstock, T. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12051967 · Cited by 13
“[14] found no significant difference between the rates of live birth among women with RPL who received micronized progesterone therapy (Utrogestan) in the first trimester and the women in a placebo group.”
BackgroundWu, H., Zhang, S., Lin, X., He, J., Wang, S., & Zhou, P. (2021) · Reproductive Biology and Endocrinology · doi:10.1186/s12958-021-00846-6 · Cited by 16
Allotey, J., Archer, L., Coomar, D., Snell, K. I. E., Smuk, M., Oakey, L. A., Haqnawaz, S., Betrán, A. P., Chappell, L. C., Ganzevoort, W., et al. (2024) · Health Technology Assessment · doi:10.3310/dabw4814 · Cited by 12
Self-citationMatar, M., Yared, G. J., Massaad, C., & Ghazal, K. (2025) · Journal of International Medical Research · doi:10.1177/03000605251315349 · Cited by 12
Casarramona, G. L., Lalmahomed, T. A., Lemmen, C. H. C., Eijkemans, M. J. C., Broekmans, F. J., Cantineau, A. E., & Drechsel, K. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.960393 · Cited by 16
“the PRISM and PROMISE trial), did not demonstrate any significant increase in risk of pregnancy or adverse neonatal outcomes (58, 59).”
MethodMEDICINAL PLANTS AND BIOLOGICALLY ACTIVE SUBSTANCES WITH ANTIFUNGAL PROPERTIES
MAR‘IN, A. A., & Коломиец, Н. Э. (2017) · Fundamental and Clinical Medicine · doi:10.23946/2500-0764-2017-2-4-45-55 · Cited by 27
Schiffer, L., Adaway, J., Baranowski, E. S., Arlt, W., & Keevil, B. G. (2018) · Annals of Clinical Biochemistry International Journal of Laboratory Medicine · doi:10.1177/0004563218780904 · Cited by 13
“Additionally, increased production and maintenance of progesterone concentrations, first by the corpus luteum and then by the placenta, is essential for the maintenance of pregnancy, and therefore progesterone administration in early pregnancy has been investigated as a potential tool to reduce preterm birth risk.(4,5…”
Sierra, S., Min, J. K., Saumet, J., Shapiro, H. M., Sylvestre, C. V., Roberts, J., Liu, K. E., Buckett, W. M., Vélez, M. P., & MAHUTTE, N. G. (2024) · Reproductive BioMedicine Online · doi:10.1016/j.rbmo.2024.104456 · Cited by 16
Immune Treatment Strategies in Unexplained Recurrent Pregnancy Loss
Rui, C., Yang, Q., Liao, Y., Qin, L., Han, J., & Gao, R. (2025) · American Journal of Reproductive Immunology · doi:10.1111/aji.70060 · Cited by 12
“However, a multicenter randomized trial on 836 women found no distinction in live birth rate outcomes between women with URPL who used vaginal micronized progesterone and those who received a placebo after a positive pregnancy test [113].”
Zhong, C., Xiong, G., Lin, L., Li, Q., Chen, X., Zhang, X., Zhang, Y., Xu, S., Wang, X., Gao, D., et al. (2022) · BMC Pregnancy and Childbirth · doi:10.1186/s12884-022-04711-1 · Cited by 13
Krishnaswamy, P. H., & Arora, R. (2019) · InnovAiT Education and inspiration for general practice · doi:10.1177/1755738019883326 · Cited by 11
“There is good evidence to suggest progesterone supplementation in early pregnancy for women with history of unexplained RPL does not improve live birth rates (Coomarasamy et al., 2015).”
Potential mechanisms and therapeutic strategies for LPS-associated female fertility decline
Qin, X. Y., Du, J., He, R., Li, Y., Li, H., & Liang, X. (2024) · Journal of Assisted Reproduction and Genetics · doi:10.1007/s10815-024-03226-2 · Cited by 11
“These disturbances have a negative impact on endometrium growth and its secretory activities, causing infertility, miscarriages, or preterm delivery [118].”
Lv, S., Yu, J., & Xu, X. (2018) · American Journal of Reproductive Immunology · doi:10.1111/aji.12856 · Cited by 11
Serum progesterone levels could predict diagnosis, completion and complications of miscarriage
Blavier, F., Blockeel, C., Cools, W., Faron, G., Santos‐Ribeiro, S., Breugelmans, M., Adriaensen, P., Fuchs, F., & Gucciardo, L. (2020) · Journal of Gynecology Obstetrics and Human Reproduction · doi:10.1016/j.jogoh.2020.101721 · Cited by 12
Pros and cons of the use of progesterone to reduce miscarriage rates
Check, J. H. (2018) · Clinical and Experimental Obstetrics & Gynecology · doi:10.12891/ceog4693.2018 · Cited by 10
ACUTE PANCREATITIS: CURRENT UNDERSTANDING OF DEVELOPMENT, DIAGNOSIS, AND TREATMENT
Подолужный, В. И. (2017) · Fundamental and Clinical Medicine · doi:10.23946/2500-0764-2017-2-4-62-71 · Cited by 13
The Importance of an Evidence-based Workup for Recurrent Pregnancy Loss
Gibbins, K. J., & Porter, T. F. (2016) · Clinical Obstetrics & Gynecology · doi:10.1097/grf.0000000000000219 · Cited by 11
PREVALENCE OF FEMALE INFERTILITY AMONG URBAN AND RURAL POPULATION IN BURYAT REPUBLIC
Юрьевич, Д. З., Atalyan, A. V., Петровна, Р. М., & Сутурина, Л. В. (2017) · Fundamental and Clinical Medicine · doi:10.23946/2500-0764-2017-2-4-14-21 · Cited by 12
Progesterone in Women with Recurrent Miscarriages
Coomarasamy, A., Hj, W., & Rai, R. (2016) · New England Journal of Medicine · doi:10.1056/nejmc1600491 · Cited by 10
Self-citationLuteal Phase Defects and Progesterone Supplementation
Collins, L. C., Gatta, L. A., Dotters-Katz, S. K., Kuller, J. A., & Schust, D. J. (2024) · Obstetrical & Gynecological Survey · doi:10.1097/ogx.0000000000001242 · Cited by 11
“Results: Endogenous progesterone plays a crucial role in the first trimester of pregnancy, and therefore, insuffi-ciencymaycontributetoRPL.”
InfluentialProgestogen for preventing miscarriage in women with recurrent miscarriage of unclear etiology
Haas, D. M., Rodriguez, M. B., Hathaway, T. J., & Ramsey, P. S. (2025) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003511.pub6 · Cited by 10
Changes in the level of fetoplacental complex hormones in pregnant women with miscarriage
Lisova, K., Кalinovska, І. V., Pryimak, S. H., Токар, П. Ю., & Varlas, V. N. (2021) · Journal of Medicine and Life · doi:10.25122/jml-2021-0089 · Cited by 14
Did the NICE guideline for progesterone treatment of threatened miscarriage get it right?
Duncan, W. C. (2022) · Reproduction and Fertility · doi:10.1530/raf-21-0122 · Cited by 9
Lou, C., Wang, C., Zhao, Q., & Jin, F. (2021) · PubMed Central · Cited by 9
Bouchard, T. P. (2023) · Medicina · doi:10.3390/medicina59010140 · Cited by 9
“The greatest benefit of progesterone for recurrent miscarriage is during the luteal phase [15], rather than after a positive pregnancy test [16], which further highlights the importance of identifying abnormal luteal phases and the early timing of progesterone supplementation.”
BackgroundImpaired endometrial function and unexplained recurrent pregnancy loss
Kuroda, K. (2019) · Hypertension Research in Pregnancy · doi:10.14390/jsshp.hrp2018-012 · Cited by 12
The role of dydrogesterone in habitual miscarriage
Polushkina, E., & Shmakov, R. G. (2020) · Meditsinskiy sovet = Medical Council · doi:10.21518/2079-701x-2020-3-74-77 · Cited by 13
Sun, D., Lu, S., Gan, X., & Lash, G. E. (2022) · Journal of Reproductive Immunology · doi:10.1016/j.jri.2022.103636 · Cited by 9
Linking autoimmunity to the origin of the adaptive immune system
Bayersdorf, R., Fruscalzo, A., & Catania, F. (2018) · Evolution Medicine and Public Health · doi:10.1093/emph/eoy001 · Cited by 10
Dhillon‐Smith, R. K., Middleton, L. J., Sunner, K. K., Cheed, V., Baker, K., Farrell-Carver, S., Bender-Atik, R., Agrawal, R., Bhatia, K., Edi-Osagie, E. C. O., et al. (2019) · Efficacy and Mechanism Evaluation · doi:10.3310/eme06110 · Cited by 10
“87 Having infertility treatment at the time of randomisation Yes 24/88 (27) 26/91 (29) 0.”
BackgroundSelf-citationDecreased level of Eomes+dCD8+ T cells with altered function might be associated with miscarriage
Chen, L., Sun, F., Li, M., Qian, J., Du, M., Li, D., & Wang, S. (2021) · Reproduction · doi:10.1530/rep-20-0639 · Cited by 8
Immunotherapy for recurrent pregnancy loss: a reappraisal
Genest, G., Almasri, W., Banjar, S., Beauchamp, C., Buckett, W. M., Dzineku, F., Demirtaş, E., Gold, P., Dahan, M. H., Jamal, W., et al. (2021) · F&S Reviews · doi:10.1016/j.xfnr.2021.11.002 · Cited by 11
“n=664) from 4 RCT (11, 13, 15, 16) Haas et al suggested that progesterone supplementation in early 212 pregnancy trended to decrease the miscarriage rate in women with ≥ 3 RPL (RR 0.”
BackgroundShen, H., Chang, W., Chen, Y., Wu, D.-L., Wen, S., & Wu, H.-C. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.831690 · Cited by 8
Preventive role of low-molecular-weight heparin in unexplained recurrent pregnancy loss
Khan, E. S., Basharat, A., Jamil, M., Ayub, S., & Khan, M. A. (2017) · South African Journal of Obstetrics and Gynaecology · doi:10.7196/sajog.2017.v23i1.1112 · Cited by 10
“A variety of treatments have been offered to couples with unexplained RPL, including lifestyle modification, progesterone therapy, human menopausal gonadotropin, in vitro fertilisation and preimplantation genetic diagnosis.[8] Anticoagulants have been studied in this context for a number of years.”
BackgroundGoruntla, N., Ganzi, N., Otturu, M., Vaddi, S. N., Mood, S. L., Suchitra, M. J., Veerabhadrappa, K. V., Ezeonwumelu, J. O. C., & Bukke, S. P. N. (2024) · The Journal of Obstetrics and Gynecology of India · doi:10.1007/s13224-024-01984-8 · Cited by 7
“There was conflict evidence about the role of progesterone in significant improvement of live births among women with a history of miscarriage [30].”
Tan, J., Xiong, Y., Zhao, P., Liu, C., Ren, Y. Q., Chen, M., Yao, G., Qian, Y., Rong, B., Qi, H., et al. (2024) · Phytomedicine · doi:10.1016/j.phymed.2024.156197 · Cited by 7
Medical and Surgical Interventions Available Before a Periviable Birth
Chien, E. K., & Gibson, K. S. (2017) · Clinics in Perinatology · doi:10.1016/j.clp.2017.01.011 · Cited by 7
Jiang, Y., Zhang, Y., Li, Y., & Che, Y. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1554875 · Cited by 7
Ashra, N., Marriott, L., Johnson, S., Abrams, K. R., & Crowther, M. J. (2020) · Scientific Reports · doi:10.1038/s41598-020-61461-w · Cited by 6
Leptin Contributes to the Development of the Corpus Luteum
Garcia, M. R. (2017) · Cell & Developmental Biology · doi:10.4172/2168-9296.1000190 · Cited by 6
“The reduced progesterone is associated with an increased occurrence of miscarriage [4], which is not mitigated with the use of synthetic progestins in subjects suffering recurrent miscarriages [5].”
BackgroundRoutine Progesterone Supplementation in Threatened Abortion: Is It a Sound Practice?
Elgergawy, A. E.-S., Abdelnaby, A. E., & Elbohoty, S. B. (2019) · Open Journal of Obstetrics and Gynecology · doi:10.4236/ojog.2019.912150 · Cited by 6
“They concluded that progesterone supplementations in early pregnancy did not increase live births in women with history of recurrent miscarriages [17].”
BackgroundMethodSun, B., Li, L., Chen, X., & Sun, Y. (2023) · BMC Pregnancy and Childbirth · doi:10.1186/s12884-023-05634-1 · Cited by 7
Habituelle Aborte – was sagt uns die neue Leitlinie?
der S2k-Leitlinie, L., Feil, K., Zschocke, J., Rudnik‐Schöneborn, S., Tempfer, C., Kuon, R., & Tóth, B. (2019) · Gynäkologische Endokrinologie · doi:10.1007/s10304-019-0244-0 · Cited by 6
Practical Work-up and Management of Recurrent Pregnancy Loss for the Front-Line Clinician
Branch, D. W., & Silver, R. M. (2016) · Clinical Obstetrics & Gynecology · doi:10.1097/grf.0000000000000216 · Cited by 36
“A large, well-done trial has shown that progesterone treatment in women with RPL and a newly positive pregnancy test is ofnobenefit.(5)”
BackgroundThe Corpus Luteum and Women’s Health
Duncan, W. C. (2016) · Springer eBooks · doi:10.1007/978-3-319-43238-0_13 · Cited by 6
Methodologic considerations in randomized clinical trials in reproductive medicine
Venetis, C. A., D’Hooghe, T., Barnhart, K. T., Bossuyt, P. M., & Mol, B. W. (2020) · Fertility and Sterility · doi:10.1016/j.fertnstert.2020.04.038 · Cited by 6
Self-citationDNA fragmentation and the ultimate success of a pregnancy
Benagiano, G., Paoli, D., Lombardo, F. P., Brosens, J. J., & Brosens, I. A. (2017) · Translational Andrology and Urology · doi:10.21037/tau.2017.03.46 · Cited by 7
“For example, several randomized-controlled trials on RPL, defined here as three consecutive pregnancy losses, reported life-births rate of 65% or more in the placebo group (14,15).”
Backgroundde Lima, J. J. A. V., Guerreiro, J., Ângelo‐Dias, M., Serra, S. S., Costa, T., Marto, N., de Pinho, J. F., Costa, J. N., Ruano, R., & Duarte, G. S. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1569819 · Cited by 8
“Among these 38 articles, 13 (31, 34, 36, 44, 46–48, 50, 51, 54, 56, 58, 61) defined RPL as two or more miscarriages, 22 (30, 33, 35, 37–43, 45, 49, 52, 53, 55, 59, 60, 62–64, 66, 67) as three or more miscarriages, and three (32, 57, 65) as four or more miscarriages (Table 1).”
Aski, S. K., Sharami, S. H., Kabodmehri, R., Rahnemaei, F. A., Milani, F., & Sabetghadam, S. (2023) · Health Science Reports · doi:10.1002/hsr2.1721 · Cited by 5
“27 In the same direction as the studies included in a review, Coomarasamy et al. 22 showed no statistical difference in congenital anomalies between the progesterone group and the placebo group.”
Interkingdom Hormonal Regulations between Plants and Animals Provide New Insight into Food Safety
Cheng, H., Wen, W., Wang, W., Yang, M.-Y., & Zhou, Y. (2023) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.3c04712 · Cited by 5
Zhao, H., He, W., Xia, C., & Yang, Z. (2024) · International Journal of Gynecology & Obstetrics · doi:10.1002/ijgo.15987 · Cited by 7
“12,13 17 In addition, progesterone can be administered for women with threatened miscarriage orally, intramuscularly, or as a vaginal suppository.”
Yovich, J. L., Mariappen, U., Hinchliffe, P. M., Dhaliwal, S. S., & Keane, K. N. (2020) · Reproductive Biology · doi:10.1016/j.repbio.2020.03.008 · Cited by 5
Scheffer, J. B., Scheffer, B. B., Aguiar, A. P., Franca, J. B., Lozano, D. H. M., & Fanchin, R. R. F. (2022) · JBRA · doi:10.5935/1518-0557.20220037 · Cited by 5
“However, another study in which progesterone supplementation was administered after a positive pregnancy test did not find a reduction in the risk of miscarriage with the use of progesterone (Coomarasamy et al., 2015).”
BackgroundEomesodermin regulate decidual CD4+T cell function during human early pregnancy
Chen, L., Li, M., Sun, F., Qian, J., Du, M., Wang, S., & Li, D. (2021) · Journal of Reproductive Immunology · doi:10.1016/j.jri.2021.103290 · Cited by 5
Youssef, A., Lashley, E. E. L. O., Vermeulen, N., & van der Hoorn, M. (2023) · BMC Pregnancy and Childbirth · doi:10.1186/s12884-023-05869-y · Cited by 5
“The ESHRE does not recommend treatment for patients with unexplained RPL, as no significant benefit was shown [13, 14].”
BackgroundDevall, A., Gallos, I. D., Khalaf, Y., Mol, B. W., Ross, J. A., Shennan, A. H., Horne, A. W., Small, R., Goddijn, M., van Wely, M., et al. (2020) · BJOG An International Journal of Obstetrics & Gynaecology · doi:10.1111/1471-0528.16358 · Cited by 5
Self-citationElenis, E., Joelsson, L. S., Stavreus-Evers, A. C., & Wånggren, K. (2024) · Fertility and Sterility · doi:10.1016/j.fertnstert.2024.12.022 · Cited by 6
Du, M., Li, M., Zhou, W., & Li, D. (2022) · Clinical and Translational Discovery · doi:10.1002/ctd2.135 · Cited by 4
Lifestyle Habits and Pregnancy Loss
Kuroda, K. (2018) · Springer eBooks · doi:10.1007/978-981-10-8690-8_9 · Cited by 5
Pruski, M., Whitehouse, D., & Bow, S. (2022) · The New Bioethics · doi:10.1080/20502877.2022.2073857 · Cited by 4
Validating Evidence and Using Standard Outcomes for Recurrent Pregnancy Loss Tests and Treatments
Scott, J. R. (2016) · Clinical Obstetrics & Gynecology · doi:10.1097/grf.0000000000000218 · Cited by 4
Oral Allylestrenol: A Pregnancy-supporting Progestogen
Malhotra, N., & Garg, R. (2017) · Journal of South Asian Federation of Obstetrics and Gynaecology · doi:10.5005/jp-journals-10006-1517 · Cited by 4
Treatment Strategy for Unexplained Recurrent Miscarriage
Kuroda, K. (2018) · Springer eBooks · doi:10.1007/978-981-10-8690-8_11 · Cited by 5
Previous Trial Studies of Unexplained Recurrent Miscarriage
Kuroda, K. (2018) · Springer eBooks · doi:10.1007/978-981-10-8690-8_8 · Cited by 4
Dispensary, K. C., Рашитович, Ш. А., Kazantsev, A. N., Dispensary, K. C., Dubovoy, A. V., Tarasov, R. S., MIRONOV, A. V., Dispensary, K. C., Рубан, Е. В., & Dispensary, K. C. (2017) · Fundamental and Clinical Medicine · doi:10.23946/2500-0764-2017-2-4-72-78 · Cited by 4
Hibberd, R., Raine‐Fenning, N., & Thornton, J. (2017) · BJOG An International Journal of Obstetrics & Gynaecology · doi:10.1111/1471-0528.14991 · Cited by 4
Kongwattanakul, K., Jatavan, P., Musigavong, O., Pranpanus, S., Salang, L., Satirapod, C., Petyim, S., & Uerpairojkit, B. (2025) · Journal of obstetrics and gynaecology research · doi:10.1111/jog.70038 · Cited by 6
“77 Furthermore, there were no significant differences between the MVP and placebo groups in live birth rates after 24 weeks of gestation (RR 1.04; 95% CI 0.94 to 1.15; p = 0.45).”
InfluentialWang, J., Li, L., Zhou, J., Pan, X., Qi, Q., Sun, H., Liu, M., & Wang, L. (2024) · Global Health & Medicine · doi:10.35772/ghm.2024.01056 · Cited by 3
Béquet, Y. L. B. N., van der Hoorn, M., Eikmans, M., Molen, R. G. V. D., le Cessie, S., van Geloven, N., Marle, M. E. V. D. A., Vermeulen, M., van den Berg, M. M. J., de Bruin, J. P., et al. (2025) · BMJ Open · doi:10.1136/bmjopen-2024-096545 · Cited by 4
“…for couples facing unexplained RPL, including human chorionic gonadotropin therapy, 23 acetylsalicylic acid, 24 heparin, 24 25 progesterone 26 (which is now only indicated in the case of vaginal blood loss in pregnancy after three or more pregnancy losses 27 ) and vitamin supplementation.”
InfluentialSelf-citationThe challenges of trials in reproductive medicine: can a Bayesian approach help?
Odendaal, J., Ryan, E., Quenby, S. M., & Gates, S. (2020) · Reproductive BioMedicine Online · doi:10.1016/j.rbmo.2020.12.009 · Cited by 3
Self-citationControversies in treatment practices of the mother-infant dyad at the limit of viability
Helou, Y. E., Buhimschi, I. A., Romano-Keeler, J., & Buhimschi, C. S. (2021) · Seminars in Perinatology · doi:10.1016/j.semperi.2021.151539 · Cited by 4
Progestogens in Threatened Miscarriage
Carp, H. (2021) · Springer eBooks · doi:10.1007/978-3-030-52508-8_4 · Cited by 3
Determinants of the economic burden of ART on the Italian NHS: insights from the Lombardy region
Listorti, E., Torbica, A., Esposito, G., Franchi, M., & Parazzini, F. (2024) · Health Economics Review · doi:10.1186/s13561-024-00583-7 · Cited by 3
Does LIN28B gene dysregulation make women more likely to abort?
Huang, Q., Niu, Y., Song, L.-J., Huang, J., Wang, C., & Ma, T. (2021) · Reproduction and Fertility · doi:10.1530/raf-21-0033 · Cited by 3
Habituelle Aborte: Diagnostik und Therapie entsprechend der S1-Leitlinie
Nawroth, F., Bohlmann, M. K., Gillessen‐Kaesbach, G., Rogenhofer, N., Tempfer, C., Wischmann, T. H., von Wolff, M., Würfel, W., & Tóth, B. (2017) · Der Gynäkologe · doi:10.1007/s00129-017-4065-8 · Cited by 3
Suthaporn, S., Jayaprakasan, K., Maalouf, W. E., Thornton, J., & Walker, K. F. (2019) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2019.12.002 · Cited by 3
Anogenital distance in newborn infants conceived by assisted reproduction and natural conception
Erçin, S., Ertaş, S., Akın, O. D., Öktem, Ö., & Yakın, K. (2020) · Reproductive BioMedicine Online · doi:10.1016/j.rbmo.2020.04.019 · Cited by 3
Early and recurrent pregnancy loss
Turocy, J. M., & Williams, Z. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-65399-2.00025-5 · Cited by 4
Diagnosis and treatment of luteal phase deficiency: a Committee Opinion
Gracia, C. R., Jain, T., Kalra, S., Pier, B., Sakkas, D., Yauger, B. J., Flyckt, R. L., Plowden, T. C., Smith, R., Senapati, S., et al. (2026) · Fertility and Sterility · doi:10.1016/j.fertnstert.2026.06.014 · Cited by 3
Regarding the evidence-based use of micronized progesterone
Makatsariya, A. D., Renzo, G. C. D., Rizzo, G., Bitsadze, V. O., Khizroeva, J. K., Blinov, D. V., Ивановна, В. Е., Govorov, I., Гурьев, Д. Л., Дикке, Г. Б., et al. (2020) · Obstetrics Gynecology and Reproduction · doi:10.17749/2313-7347/ob.gyn.rep.2020.171 · Cited by 2
Diagnostik und Therapie wiederholter Spontanaborte gemäß S2k-Leitlinie
Nawroth, F., & Tóth, B. (2023) · Die Gynäkologie · doi:10.1007/s00129-022-05039-9 · Cited by 2
A rapid improvement event: progesterone prescribing in prevention of miscarriage
Bolger, L., O’Riordan, N., & Allen, C. (2024) · BMJ Open Quality · doi:10.1136/bmjoq-2023-002517 · Cited by 2
CONTROVERSIAL ISSUES OF SAPRONOSES AND POSSIBLE SOLUTIONS
Ab, B. (2017) · Fundamental and Clinical Medicine · doi:10.23946/2500-0764-2017-2-4-34-44 · Cited by 2
Shen, S., Chen, Q.-Z., Zhang, L.-F., He, J., Lu, J., Li, W., Xiao, W., Zhou, Z.-H., Morse, A. N., Cheng, K. K., et al. (2018) · The Journal of Maternal-Fetal & Neonatal Medicine · doi:10.1080/14767058.2018.1540580 · Cited by 2
“venting miscarriage in early to midpregnancy [29,30].”
Self-citationDydrogesterone in the treatment of the threatened and habitual miscarriage
Картлосовна, Т. Н., & Агаджанова, А. А. (2018) · Meditsinskiy sovet = Medical Council · doi:10.21518/2079-701x-2018-13-68-72 · Cited by 2
The efficacy of enoxaparin for recurrent abortion: a meta-analysis of randomized controlled studies
Liu, Y., Shan, N., Yuan, Y. J., Tan, B., Che, P., & Qi, H. (2019) · The Journal of Maternal-Fetal & Neonatal Medicine · doi:10.1080/14767058.2019.1608433 · Cited by 2
Romanenko, T. G., & Sulimenko, O. M. (2018) · Reproductive Endocrinology · doi:10.18370/2309-4117.2018.42.60-66 · Cited by 3
Luteal phase support as one of key factors of success in assisted reproduction
Kamilova, D. P., Yakunina, N. A., & Ketiladze, T. M. (2019) · Russian Journal of Human Reproduction · doi:10.17116/repro20192504151 · Cited by 2
Beurteilung und Therapie der Lutealphase
Sonntag, B. (2019) · Springer Reference Medizin · doi:10.1007/978-3-662-57636-6_8 · Cited by 2
Sbracia, M., Scarpellini, F., & Stamenov, G. (2020) · Human Reproduction · doi:10.1093/humrep/deaa078 · Cited by 2
Should Endometrium be Sampled in Cases of Recurrent Pregnancy Loss?
Arora, R., Sachdeva, M., Rathee, A., & Agarwal, U. (2023) · Journal of South Asian Federation of Obstetrics and Gynaecology · doi:10.5005/jp-journals-10006-2164 · Cited by 1
Agarwal, N., Gupta, S., Kulshrestha, V., Yadav, R. K., Kriplani, A., Kachhawa, G., & Bhatla, N. (2024) · The Journal of Obstetrics and Gynecology of India · doi:10.1007/s13224-023-01933-x · Cited by 1
“PROMISE trial also did not find significant difference in live birth in women receiving twice daily vaginal suppositories containing 400 mg micronized progesterone till 12 weeks gestation ( p = 0.45) [16].”
InfluentialCHECK, J. H., & Neumann, B. (2024) · Gynecology & Reproductive Health · doi:10.33425/2639-9342.1248 · Cited by 9
“This applies to the question as to whether corpus luteum inadequacy can be a cause of frequent pregnancy loss, and whether P supplementation can reduce the risk of miscarriage [17].”
BackgroundInfluentialProgestogen supplementation to prevent miscarriage: Evidence and controversies
Saccone, G., Berghella, V., Gulersen, M., & Sardo, A. D. S. (2026) · International Journal of Gynecology & Obstetrics · doi:10.1002/ijgo.70793 · Cited by 1
Luteal Phase Defects and Progesterone Supplementation
Collins, L. C., Gatta, L. A., Dotters-Katz, S. K., Kuller, J. A., & Schust, D. J. (2024) · Topics in Obstetrics & Gynecology · doi:10.1097/01.pgo.0001028016.32068.b4 · Cited by 1
Immunologie: Diagnostik und Therapie
Kuon, R., & Tóth, B. (2016) · Springer eBooks · doi:10.1007/978-3-662-50424-6_18 · Cited by 1
Idiopathische rezidivierende Aborte
Tempfer, C. (2016) · Springer eBooks · doi:10.1007/978-3-662-50424-6_19 · Cited by 1
Early Pregnancy Support: Evidence-Based Management
Kandavel, V., & Quenby, S. M. (2016) · Springer eBooks · doi:10.1007/978-3-319-42858-1_6 · Cited by 1
Self-citation
Metadata
- Authors
- Coomarasamy, A., Williams, H., Truchanowicz, E., Seed, P. T., Small, R., Quenby, S., Gupta, P., Dawood, F., Koot, Y. E. M., Bender Atik, R., Bloemenkamp, K. W. M., Brady, R., Briley, A. L., Cavallaro, R., Cheong, Y. C., Chu, J. J., Eapen, A., Ewies, A., Hoek, A., Kaaijk, E. M., Koks, C. A. M., Li, T.-C., MacLean, M., Mol, B. W., Moore, J., Ross, J. A., Sharpe, L., Stewart, J., Vaithilingam, N., Farquharson, R. G., Kilby, M. D., Khalaf, Y., Goddijn, M., Regan, L., & Rai, R.
- Affiliations
- St Thomas' Hospital (GB)
- University of Birmingham (GB)
- Heart of England NHS Foundation Trust (GB)
- University of Warwick (GB)
- Liverpool Womens NHS Foundation Trust (GB)
- University Medical Center Utrecht (NL)
- Leiden University Medical Center (NL)
- Imperial College London (GB)
- Princess Anne Hospital (GB)
- Sandwell & West Birmingham Hospitals NHS Trust (GB)
- University of Groningen (NL)
- OLVG (NL)
- Máxima Medisch Centrum (NL)
- Royal Hallamshire Hospital (GB)
- University Hospital Crosshouse (GB)
- The University of Adelaide (AU)
- Nottingham University Hospitals NHS Trust (GB)
- King's College Hospital NHS Foundation Trust (GB)
- Newcastle upon Tyne Hospitals NHS Foundation Trust (GB)
- Portsmouth Hospitals NHS Trust (GB)
- Guy's and St Thomas' NHS Foundation Trust (GB)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-11-26
- Volume
- 373
- Issue
- 22
- Pages
- 2141-2148
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2236902456
- Cited by
- 312
- References
- 22
- Citations by year
- 2026: 17 · 2025: 22 · 2024: 24 · 2023: 24 · 2022: 22 · 2021: 33 · 2020: 35 · 2019: 28 · 2018: 38 · 2017: 36 · 2016: 30 · 2015: 1
- FWCI
- 17.23
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (publishedVersion, other-oa)
- University of Birmingham Research Portal (University of Birmingham) (acceptedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Leiden Repository (Leiden University) (submittedVersion)
- Adelaide Research & Scholarship (AR&S) (University of Adelaide) (submittedVersion)
- Utrecht University Repository (Utrecht University) (submittedVersion)
- ePrints Soton (University of Southampton) (submittedVersion)
- Research Portal (King's College London) (submittedVersion, other-oa)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion)
- Spiral (Imperial College London) (submittedVersion)
- Utrecht University Repository (Utrecht University) (submittedVersion, other-oa)
- Funders
- National Institute for Health and Care Research (08/38/01)
- Medical Research Council
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Reproductive System and Pregnancy
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Pregnancy and Medication Impact
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Reproductive Health and Contraception
- Keywords
- progesterone supplementation, recurrent pregnancy loss, unexplained recurrent spontaneous abortion, first trimester, live birth rate, micronized progesterone, miscarriage, neonatal survival
- MeSH terms
- Abortion, Habitual, Administration, Intravaginal, Adult, Double-Blind Method, Female, Gestational Age, Humans, Pregnancy, Pregnancy Trimester, First, Progesterone, Body Mass Index, Treatment Failure, Live Birth
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.